Advances in contact lens materials to extend wear time for a new standard in vision correction and future medical devices
隐形眼镜材料的进步可延长佩戴时间,从而达到视力矫正和未来医疗设备的新标准
基本信息
- 批准号:9255935
- 负责人:
- 金额:$ 22.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2018-08-31
- 项目状态:已结题
- 来源:
- 关键词:3-DimensionalAcanthamoeba KeratitisAddressAdolescentAdverse effectsAffectAppearanceAreaAstigmatismBlood capillariesClinical ResearchComplexContact LensesConvectionCorneaCorneal TopographyCosmeticsDevicesDimensionsDrug Delivery SystemsDrug MonitoringDrynessElderlyEmerging TechnologiesEngineeringEnvironmentEyeglassesFilmFutureGasesGenerationsGlaucomaGoalsGrowth FactorHealthHealth Care CostsHormonesHydrogelsHydrophilic Contact LensesHydrophobicityHyperopiaHypoxiaImageInfectionInflammationLaser In Situ KeratomileusisLeadLong-Term EffectsMeasurableMeasuresMedical DeviceMethodsModalityMoldsMolecular ConformationMonitorMorphologyMyeloma ProteinsMyopiaNanotechnologyNeedlesNutrientOperative Surgical ProceduresOpticsOptometryOxygenPatientsPeptidesPerformancePermeabilityPhasePhotorefractive KeratectomyPolymersPolynomial ModelsPopulationPresbyopiaPrintingProblem SolvingProcessProductionPropertyProteinsRednessRiskShapesSiliconSiliconesStructureSurfaceSurface TensionTechnologyTimeVisionVisualVisual AcuityWaterantimicrobial drugbasebiomaterial compatibilitycapillarycommercializationcopolymercostdesignimprovedinnovationlensmolecular assembly/self assemblymonitoring devicenovelpatient populationprototypesubmicronsurface coatingsurfactantwasting
项目摘要
PROJECT SUMMARY
Over the last two decades, the commercialization of silicone-hydrogel ("SiHy") composite technologies has led to new
soft CLs that are more breathable, comfortable, and affordable, including in daily disposable versions which have
considerably broadened the customer base, especially among younger generations. Despite these improvements,
the major persistent problem facing contact lenses is their poor compatibility with ocular environment, particularly the
tear film. While the softness of the new composite materials made lenses more comfortable by conforming better to
the cornea, the resultant tight fitting considerably lowers the tear exchange rate in the post-lens tear film. In addition,
the precision of lens design and fabrication, limited by the difficulties of the thermal expansion of a dual-domain (silicon
and hydrogel) substrate, are adequate only for adjusting an image's focus, not its visual acuity caused by other higher-
order optical aberrations. We propose to solve these issues by creating a novel contact lens material that will lead to
a new best-in-class soft lens with significant improvements in vision correction, clarity and comfort, and wide
applicability to numerous patient populations.
This project will engineer the new generation of lens innovations based on several recent advances in material and
fabrication nanotechnologies. The combined application of submicron morphology control, molecular self-assembly,
and high-precision molding (as well as 3-D printing), will make future CL devices more precise, biocompatible, and
versatile. We identified three major areas of improvement in CLs that will benefit from our implementation of such new
emerging technologies: (a) Pre-synthesis of new silicone block-copolymers for higher-precision control of domain
morphology during lens fabrication, (b) Application of high-precision fabrication and high-definition ("HD") design for
correcting the spherical aberration of CLs, and (c) Engineering a novel design of lens material and surface coating for
enhancing PLTF turnover to improve ocular health.
The new product would widely replace current CLs for at least the 39 million patients in the US market, and likely
expand this market significantly with new and valuable functions such as control of myopia progression for adolescents
and night vision enhancements for the elderly (by high-precision control and high-definition design), as well as
unprecedented comfort and biocompatibility (by new surface coating's enhancement of PLTF turnover). Further, the
new level of comfort and extended wear time would solve one key challenge associated with current state-of-the-art
in ocular drug delivery and monitoring devices, promoting our technology to a future platform for growing these
applications to treat other large populations such as the 64 million glaucoma patients worldwide.
项目摘要
在过去的二十年中,硅酮-水凝胶(“SiHy”)复合材料技术的商业化已经导致了新的应用。
更透气、更舒适、更实惠的柔软CL,包括具有
大大扩大了客户群,尤其是年轻一代。尽管有这些改进,
接触镜面临的主要持续问题是它们与眼环境的相容性差,特别是
泪膜虽然新复合材料的柔软性使镜片更舒适,
角膜,由此产生的紧密配合大大降低了镜片后泪液膜中的泪液交换率。此外,本发明还提供了一种方法,
透镜设计和制造的精度受到双畴(硅)热膨胀困难的限制
和水凝胶)基质,仅足以调节图像的焦点,而不是由其他更高-
阶光学像差。我们建议通过创造一种新的接触透镜材料来解决这些问题,
一种新型的同类最佳软性透镜,在视力矫正、清晰度和舒适度方面都有显著改进,
适用于众多患者群体。
该项目将根据材料和光学技术的最新进展设计新一代透镜创新。
制造纳米技术。亚微米形貌控制、分子自组装、
和高精度成型(以及3D打印),将使未来的CL设备更精确,生物相容性,
多才多艺我们确定了CL的三个主要改进领域,这些改进将受益于我们实施这些新的
新兴技术:(a)预合成新的有机硅嵌段共聚物,以更精确地控制微区
(B)高精度制造和高清晰度(“HD”)设计在透镜制造期间的应用,
校正CL的球面像差,以及(c)设计新的透镜材料和表面涂层,
增强PLTF周转以改善眼部健康。
新产品将广泛取代目前的CL,至少有3900万患者在美国市场,并可能
通过控制青少年近视进展等新的有价值的功能显着扩大这一市场
和老年人夜视增强(通过高精度控制和高清晰度设计),以及
前所未有的舒适性和生物相容性(通过新的表面涂层增强PLTF周转)。此夕h
新的舒适度和更长的佩戴时间将解决与当前最先进技术相关的一个关键挑战
在眼部药物输送和监测设备,促进我们的技术,以发展这些未来的平台
应用于治疗其他大量人群,例如全球6400万青光眼患者。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Roman Domszy其他文献
Roman Domszy的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Roman Domszy', 18)}}的其他基金
Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response
环孢素 A 持续递送技术治疗自身免疫反应
- 批准号:
10256580 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Sustained delivery technology for Cyclosporine A in the treatment of autoimmune response
环孢素 A 持续递送技术治疗自身免疫反应
- 批准号:
10698850 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
相似海外基金
Latrunculin B as a new drug lead for the treatment of Acanthamoeba keratitis
Latrunculin B 作为治疗棘阿米巴角膜炎的新药先导物
- 批准号:
10192287 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Investigation of the pathogenic mechanisms of Acanthamoeba Keratitis
棘阿米巴角膜炎发病机制的探讨
- 批准号:
18K16938 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Latrunculin B as a new drug lead for the treatment of Acanthamoeba keratitis
Latrunculin B 作为治疗棘阿米巴角膜炎的新药先导物
- 批准号:
10391540 - 财政年份:2021
- 资助金额:
$ 22.5万 - 项目类别:
Development of early diagnostic method and elucidation of pathogenic mechanism for Acanthamoeba keratitis
棘阿米巴角膜炎早期诊断方法的建立及致病机制的阐明
- 批准号:
16K20310 - 财政年份:2016
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
The efficacy of the photodynamic therapy (PDT) against Acanthamoeba keratitis
光动力疗法(PDT)治疗棘阿米巴角膜炎的疗效
- 批准号:
25861635 - 财政年份:2013
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Early diagnosis with in vivo laser confocal microscopy incytomegalovirus corneal endotheliitis and Acanthamoeba keratitis
体内激光共聚焦显微镜早期诊断巨细胞病毒角膜内皮炎和棘阿米巴角膜炎
- 批准号:
23890072 - 财政年份:2011
- 资助金额:
$ 22.5万 - 项目类别:
Grant-in-Aid for Research Activity Start-up
BIOLOGY, IMMUNOLOGY & THERAPY OF ACANTHAMOEBA KERATITIS
生物学、免疫学
- 批准号:
6258589 - 财政年份:1995
- 资助金额:
$ 22.5万 - 项目类别:














{{item.name}}会员




